Mr. Young is a Managing Director of Longitude Capital. Prior to joining Longitude Capital in 2022, Mr. Young was the Chief Operating Officer and Chief Financial Officer of GRAIL, a developer of blood cancer tests that was acquired by Illumina (ILMN) for $8 billion in 2021. From 2013 to 2019, Mr. Young held positions of increasing responsibility at Jazz Pharmaceuticals (JAZZ), a Longitude portfolio company, most recently as Executive Vice President and Chief Financial Officer. Prior to Jazz, Mr. Young was an investment banker for nearly 20 years at Barclays Capital, Citigroup, Lehman Brothers, and Merrill Lynch, where he advised and led financings for hundreds of emerging and established life science companies.

Additionally, Mr. Young served on the board of PRA Health Sciences (PRAH) until its acquisition by ICON plc for $12 billion in 2021, and currently serves as Lead Independent Director and Chairman of the Audit Committee of CytomX Therapeutics (CTMX). Mr. Young currently serves on the boards of AllinBio, Alpha-9 Oncology, and OrsoBio. He also led Longitude Capital’s investment in Aviceda Therapeutics and Mirum Pharmaceuticals (MIRM). Mr. Young holds an MBA and a BS in Economics from the Wharton School of the University of Pennsylvania.